Orgenesis sees 3Q revenue rise by 40%, driven by rapid progress in its point-of-care network – Proactive Investors USA & Canada
stemadminMesenchymal Stem CellsNo comments

For the quarterended September 30, the Germantown, Maryland-based company reported revenue of $1.7 million, compared to $1.2 million in the same period in 2019 Inc () (FRA:45O) posted third-quarter results on Thursday that saw its revenue jump 40% year-over-year on the back of growth in its Point of Care (POCare) cell and gene therapy (CGT) network. For the periodended September 30, 2020, the Germantown, Maryland-based company reported revenue of $1.7 million, compared to $1.2 million in the same period in 2019.

Read more
A Review of Stem Cell-Based Therapies for Parkinson Disease – AJMC.com Managed Markets Network
stemadminMesenchymal Stem CellsNo comments

Researchers discuss the development and potential of stem cellbased therapies in the treatment of Parkinson disease. In assessing treatment for Parkinson disease (PD), the current standard of care involves levodopa, potentially in combination with carbidopa, to address the loss of dopamine known to occur as the condition progresses. However, several innovations in therapy for PD have occurred in recent years, particularly deep brain stimulation and the potential use of stem cells

Read more
Sales of the Mesenchymal Stem Cells Market to Anticipated to Exceed US$ XX by2020 – TechnoWeekly
stemadminMesenchymal Stem CellsNo comments

In this report, the global Mesenchymal Stem Cells market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025

Read more
JadiCell Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double…
stemadminMesenchymal Stem CellsNo comments

OCEANSIDE, Calif., Oct. 28, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported today a publication from the University of Miami1, demonstrating intravenous administration of JadiCells results in a significant survival improvement in COVID-19 patients

Read more
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute…
stemadminMesenchymal Stem CellsNo comments

Oct. 28, 2020 12:00 UTC ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.(AgeX: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, and Imstem Biotechnology, Inc.

Read more
Mesenchymal Stem Cells Market To Exceed Revenues Worth US$ By The End Of2020 – PRnews Leader
stemadminMesenchymal Stem CellsNo comments

This report presents the worldwide Mesenchymal Stem Cells market size (value, production and consumption), splits the breakdown (data status 2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis

Read more
AgeX Therapeutics Inc. [AGE] is -6.59% lower this YTD. Is it still time to buy? – The DBT News
stemadminMesenchymal Stem CellsNo comments

AgeX Therapeutics Inc. [AMEX: AGE] traded at a low on 10/28/20, posting a -9.57 loss after which it closed the day session at $1.70. The company report on October 28, 2020 that AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome.

Read more

Theme: Illdy.